KDM1A and melanoma: Because LSD1 is overexpressed in a number of human cancers (acute myeloid leukemia, neuroblastoma, retinoblastoma, prostate cancer, breast cancer, lung cancer, and bladder cancer and melanoma types) [32,33,34], the protein has emerged as an important target for the development of specific inhibitors as a new class of antitumor agents (Figure 1) [35,36].